Skip to main content

Lexicon Pharmaceuticals Value Stock - Dividend - Research Selection

Lexicon Pharmaceuticals

ISIN: US5288723027, WKN: A14SSK

Market price date: 26.05.2021
Market price: 4,31 USD

Lexicon Pharmaceuticals Fundamental data and company key figures of the share

Annual reports in USD
Key figures 15-03-2021
Cash flow
Net operating cash flow -142.969.000
Capital Expenditures -87.000
Free cash flow -143.056.000
Balance sheet
Total Equity 156.371.000
Liabilities & Shareholders equity 203.788.000
Income statement
Net income -58.574.000
Eps (diluted) -0,530
Diluted shares outstanding 110.840.000
Net sales/revenue 23.995.000

Fundamental ratios calculated on: 26-05-2021

Key figures 26-05-2021
Cash flow
P/C -3,34
P/FC -3,34
Balance sheet
Income statement
Div. Yield0,00%

Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.

Market Capitalization477.720.384,00 USD
IndicesNASDAQ Comp.
Raw Data SourceUS GAAP in Millionen USD
Stock Split2015-05-21,1.0000/7.0000

Description of the company

Lexicon Pharmaceuticals, Inc. (Lexicon Pharmaceuticals) is a biopharmaceutical company focused on the discovery and development of breakthrough treatments for human disease. Lexicon Pharmaceuticals uses its gene knockout technologies and an integrated platform of medical technologies to study the physiological and behavioral functions of almost 5,000 genes in mice and assessed the utility of the proteins encoded by the corresponding human genes as drug targets. It has five drug programs in various stages of clinical development and has advanced small molecule compounds from a number of additional drug programs into various stages of preclinical development and research. Its drug program includes LX4211, LX1032, LX1033, LX2931 and LX7101.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources::,,